{"id":"vayarin-supplementation-of-n-3-pufa","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Gastrointestinal discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"The n-3 PUFAs in Vayarin®, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are essential for maintaining the integrity of neuronal membranes and modulating inflammation, which can improve cognitive function and behavior in individuals with certain neurological conditions.","oneSentence":"Vayarin® provides a targeted delivery of n-3 polyunsaturated fatty acids (PUFAs) to support brain health and function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:40:20.244Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents"}]},"trialDetails":[{"nctId":"NCT02348073","phase":"PHASE3","title":"Efficacy of Phosphatidylserine Enriched With n-3 PUFA Supplementation on ADHD in Children With Epilepsy","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-03","conditions":"Attention Deficit Disorder With Hyperactivity, ADHD Inattention or Mixed Type, Epilepsy","enrollment":77}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1402,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Vayarin®, supplementation of n-3 PUFA","genericName":"Vayarin®, supplementation of n-3 PUFA","companyName":"Hospices Civils de Lyon","companyId":"hospices-civils-de-lyon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vayarin® provides a targeted delivery of n-3 polyunsaturated fatty acids (PUFAs) to support brain health and function. Used for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}